Lee Chow H
Chemistry Program, University of Northern British Columbia, Prince George, British Columbia V2N 4Z9, Canada.
Curr Med Chem Anticancer Agents. 2004 Jan;4(1):43-52. doi: 10.2174/1568011043482197.
One of the main reasons for the failure in cancer chemotherapy is the existence of multidrug resistance (MDR) mechanisms. One form of MDR phenotype is contributed by a group of plasma membrane proteins that belong to a large superfamily of proteins called the ATP-binding cassette (ABC) transporters. There has been intense search for compounds, which can act at reversing MDR phenotype exhibited by ABC transporters such as P-glycoprotein (P-gp), multidrug-resistance protein (MRP) and breast cancer resistance protein (BCRP). Reversing agents can be designed to target MDR-associated ABC transporters at three levels - the protein, mRNA or DNA level. This review aims at describing, over-viewing and discussing currently known MDR reversing agents, which have been shown to act at either of the three levels against ABC transporters. Other potential agents and strategies, which can be used to reverse the MDR phenotype, are also discussed.
癌症化疗失败的主要原因之一是存在多药耐药(MDR)机制。MDR表型的一种形式是由一组质膜蛋白导致的,这些蛋白属于一个名为ATP结合盒(ABC)转运蛋白的大型蛋白质超家族。人们一直在积极寻找能够逆转ABC转运蛋白(如P-糖蛋白(P-gp)、多药耐药蛋白(MRP)和乳腺癌耐药蛋白(BCRP))所表现出的MDR表型的化合物。逆转剂可以设计成在三个水平上靶向与MDR相关的ABC转运蛋白——蛋白质、mRNA或DNA水平。这篇综述旨在描述、概述和讨论目前已知的MDR逆转剂,这些逆转剂已被证明能在上述三个水平中的任一水平上作用于ABC转运蛋白。还讨论了可用于逆转MDR表型的其他潜在药物和策略。